{"id":"NCT01707992","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","officialTitle":"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-20","primaryCompletion":"2015-04-13","completion":"2017-07-04","firstPosted":"2012-10-16","resultsPosted":"2019-03-13","lastUpdate":"2021-11-09"},"enrollment":2199,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Laquinimod","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo-Controlled Phase: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Placebo-Controlled Phase: Laquinimod 0.6 mg","type":"EXPERIMENTAL"},{"label":"Placebo-Controlled Phase: Laquinimod 1.2 mg","type":"EXPERIMENTAL"},{"label":"Active Treatment Phase: Laquinimod 0.6 mg","type":"EXPERIMENTAL"},{"label":"Active Treatment Phase: Laquinimod 1.2 mg","type":"EXPERIMENTAL"},{"label":"Active Treatment Phase: Off Drug","type":"NO_INTERVENTION"}],"summary":"This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).","primaryOutcome":{"measure":"Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months)","timeFrame":"Baseline to Month 24","effectByArm":[{"arm":"Placebo-Controlled Phase: Placebo","deltaMin":73,"sd":null},{"arm":"Placebo-Controlled Phase: Laquinimod 0.6 mg","deltaMin":66,"sd":null},{"arm":"Placebo-Controlled Phase: Laquinimod 1.2 mg","deltaMin":69,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.7057"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":284,"countries":["United States","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Croatia","Czechia","Estonia","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Latvia","Moldova","Montenegro","North Macedonia","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["34378456"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":727},"commonTop":["Headache","Nasopharyngitis","Back pain","Anaemia","Respiratory tract infection viral"]}}